CA2380979A1 - Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci - Google Patents

Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci Download PDF

Info

Publication number
CA2380979A1
CA2380979A1 CA002380979A CA2380979A CA2380979A1 CA 2380979 A1 CA2380979 A1 CA 2380979A1 CA 002380979 A CA002380979 A CA 002380979A CA 2380979 A CA2380979 A CA 2380979A CA 2380979 A1 CA2380979 A1 CA 2380979A1
Authority
CA
Canada
Prior art keywords
mbl
receptor antagonist
lectin
complement activation
mbl receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380979A
Other languages
English (en)
Inventor
Gregory L. Stahl
Robert Lekowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2380979A1 publication Critical patent/CA2380979A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des techniques et des produits permettant de réguler la voie du complément à lectine associé à l'activation du complément (LPC). Ces techniques comprennent des techniques in vitro et in vivo qui permettent d'inhiber l'activation du complément associée à la LCP. Ces techniques consistent à mettre en contact une cellule de mammifère possédant un ligand de la lectine mannose-spécifique (MBL) exposé en surface avec une quantité efficace d'un antagoniste des récepteurs de la lectine mannose-spécifique, afin d'inhiber l'activation du complément associée à la LCP. L'antagoniste des récepteurs de la lectine mannose-spécifique peut être administré à un sujet, afin d'empêcher une lésion cellulaire induite par l'activation du complément associée à la LCP. Les produits de l'invention sont des compositions d'un antagoniste des récepteurs de la lectine mannose-spécifique. L'antagoniste des récepteurs de la lectine mannose-spécifique est un peptide isolé se fixant à ladite lectine mannose-spécifique, qui se lie sélectivement à un épitope de la lectine mannose-spécifique humaine, et qui inhibe l'activation du complément associée à la LCP.
CA002380979A 1999-08-13 2000-08-14 Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci Abandoned CA2380979A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14881599P 1999-08-13 1999-08-13
US60/148,815 1999-08-13
PCT/US2000/022123 WO2001012212A1 (fr) 1999-08-13 2000-08-14 Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
CA2380979A1 true CA2380979A1 (fr) 2001-02-22

Family

ID=22527516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380979A Abandoned CA2380979A1 (fr) 1999-08-13 2000-08-14 Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci

Country Status (5)

Country Link
EP (1) EP1204419A1 (fr)
JP (1) JP2003507338A (fr)
AU (1) AU781805B2 (fr)
CA (1) CA2380979A1 (fr)
WO (1) WO2001012212A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
NZ523900A (en) 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
DE10130985B4 (de) 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
EP2422812A1 (fr) * 2003-02-21 2012-02-29 Genentech, Inc. Procédés pour prévenir et traiter des lésions tissulaires associées à une lésion de reperfusion d'ischémie
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006131874A2 (fr) * 2005-06-06 2006-12-14 Univ Cape Town Procedes de traitement ou de prophylaxie de l'atherosclerose et d'une lesion de reperfusion
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
US20110293524A1 (en) * 2008-02-29 2011-12-01 The Brigham and Women"s Hosptial Inc. Methods and compositions for the regulation of lectin complement pathway (lcp)-associated complement activation in hyperglycemic myocardial damage
CA2971474C (fr) 2009-10-16 2022-11-22 Omeros Corporation Methodes pour traiter la coagulation intravasculaire disseminee par inhibition de l'activation du complement dependante de masp-2
GEP20247583B (en) * 2015-11-09 2024-01-10 Univ Leicester Methods for treating condi tions associated with masp-2 dependent complement activation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
DE19806185C2 (de) * 1998-02-02 1999-11-18 Biogenes Gmbh Immunoassay und Testkit zur Bestimmung von fucosyliertem Protein in einer biologischen Probe
EP1140171A4 (fr) * 1998-12-15 2002-03-13 Brigham & Womens Hospital Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine

Also Published As

Publication number Publication date
WO2001012212A1 (fr) 2001-02-22
AU6637000A (en) 2001-03-13
AU781805B2 (en) 2005-06-16
EP1204419A1 (fr) 2002-05-15
JP2003507338A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
US11458187B2 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
US20230112931A1 (en) Plasma kallikrein binding proteins
AU781805B2 (en) Inhibitors of the lectin complement pathway (LCP) and their use
US20030124631A1 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
EP2217238B1 (fr) Procédés et compositions pour le traitement de maladies protéinuriques
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
WO2000035483A1 (fr) Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
CA2525291A1 (fr) Peptides de liaison specifique p. aeruginosa mucoid exopolysaccharide
US7662382B2 (en) Inducible ligand for α1β1 integrin and uses
US20210179717A1 (en) Antibodies against mac-1
EP1154785A2 (fr) Inhibiteurs utilises dans l'hemostase et la fonction immunitaire
US20070167369A1 (en) Novel use of isolated polypeptide comprising four FAS-1 domains, EM1 domain and RGD motif
JP2004511526A (ja) 酸化タンパク質、およびその生物活性、該活性メカニズム、該タンパク質の使用およびその阻害から誘導される治療的かつ診断的方法
TWI432211B (zh) 與登革病毒相關之胜肽及抗體以及其用途
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema
Hui Biochemical and functional studies of a novel complement inhibitor, CRIT, with its interaction partners
KR20130002826A (ko) Ｔｌｔ-6 단백질에 대한 항체 및 그 응용

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead